Botox
Forehead lines
Approved
Approval (third indication) announced October 3, 2017.
Depatuxizumab mafodotin ABT-414
Glioblastoma (rGBM)
Phase 3
Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Phase 3
Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved
Approved November 13, 2013.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved
Approved February 12, 2014.
Imbruvica
Deletion 17p
Approved
Approved July 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved
Approved December 19, 2014.
IMBRUVICA
Waldenström’s Macroglobulinemia
Approved
Approved January 29, 2015 - PCYC
ABBV-8E12
Alzheimer's disease
Phase 2
Phase 2 initiation announced January 25, 2017.
ATOGEPANT
Chronic migraine
Phase 3
Phase 3 trial met primary endpoint - July 29, 2020.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3
Phase 3 data due 2021.
ABICIPAR
Age-related macular degeneration (AMD)
CRL
CRL issued June 26, 2020.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
Approved
Approved January 19, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved
Approved September 14, 2017.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Approved
Approval announced June 11, 2018.
Venetoclax - CANOVA
Relapsed or refractory multiple myeloma
Phase 3
Phase 3 data due in 2021.
Risankizumab
Psoriasis
Approved
FDA approval announced April 23, 2019.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approved
Approval announced August 2, 2017.
ABT-494
Psoriatic Arthritis
Phase 3
Phase 3 trial to commenced 2017.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Upadacitinib
Atopic Dermatitis
sNDA Filing
Regulatory filing announced October 19, 2020.
Imbruvica
Marginal zone lymphoma
Approved
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Approved
Approval announced August 3, 2017.
Elagolix
Uterine Fibroids
Approved
FDA approval announced May 29, 2020.
Elagolix
Endometriosis
Approved
FDA approval announced July 24, 2018.
Ubrogepant
Migraine
Approved
FDA Approval announced December 23, 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Approved
FDA Approval announced August 16, 2019.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU)
First-line Small Cell Lung Cancer
Phase 3
Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Approved
FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Approved
FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta
First line unfit AML
Approved
FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
Phase 3
Phase 3 trial met primary and secondary endpoints - December 9, 2020.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
Phase 3
FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3
Phase 3 primary endpoint not met (PFS/OS).
Venclexta BELLINI
Multiple myeloma
Phase 3
Phase 3 primary endpoint met.
Botox
Lower limb spasticity
Approved
FDA Approval announced October 24, 2019.
Botox
Upper limb spasticity
Approved
FDA Approval announced June 21, 2019.
Venetoclax and obinutuzumab
Chronic lymphocytic leukemia
sNDA Filing
sNDA filing announced June 4, 2019.
Juvéderm VOLUMA
Mid-Face Injection Via Cannula
Approved
FDA Approval announced September 3, 2019.
Veliparib
Ovarian cancer
Phase 3
Phase 3 presentation at ESMO 28 September 2019.
Risankizumab ( LIMMITLESS )
Psoriasis
Phase 3
Phase 3 data presented at EADV October 10, 2019.
IMBRUVICA (ibrutinib) and rituximab
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approved
FDA Approval announced April 21, 2020.
Risankizumab vs secukinumab
Plaque psoriasis
Phase 3
Phase 3 trial met primary endpoint - January 14, 2020.
Upadacitinib
Psoriatic arthritis
PDUFA
sNDA filing announced June 1, 2020. PDUFA estimate April 1, 2021.
Risankizumab MOTIVATE
Crohn’s Disease
Phase 3
Phase 3 trial met primary endpoint - January 7, 2021.
Risankizumab KEEPSAKE2
Psoriatic Arthritis
Phase 3
Phase 3 trial met primary endpoint - January 5, 2021.
Upadacitinib
Atopic dermatitis
Phase 3
Phase 3 data met co-primary endpoints - June 18, 2020. Second Phase 3 trial also met primary endpoint - July 21, 2020.
Venclexta (VIALE-A)
Acute Myeloid Leukemia (AML)
Approved
FDA approval announced October 16, 2020.
Imbruvica + Venclexta (CAPTIVATE)
Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Phase 2
Phase 2 trial ongoing.
Ibrutinib in combination with prednisone
Chronic Graft Versus Host Disease
Phase 3
Phase 3 trial ongoing.
ABBV-951
Parkinson's disease
Phase 3
Phase 3 data due late-2021.
Ibrutinib
COVID-19
Phase 2
Phase 2 trial has been initiated.
JUVÉDERM VOLUMA
Augmentation of the chin region
Approved
FDA Approval announced June 15, 2020.
Botox
Neurogenic Detrusor Overactivity
PDUFA
sBLA filing accepted June 22, 2020. PDUFA date 1Q 2021.
Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant)
COVID-19 (severe)
Phase 2
Phase 2 trial initiation announced August 3, 2020.
RINVOQ (upadacitinib)
Active Ankylosing Spondylitis
PDUFA
sNDA filing announced August 25, 2020. PDUFA estimate June 25, 2020.
AGN-190584
Presbyopia
Phase 3
Phase 3 trial met primary endpoint - October 28, 2020.